Skip to main
TYRA

Tyra Biosciences (TYRA) Stock Forecast & Price Target

Tyra Biosciences (TYRA) Analyst Ratings

Based on 10 analyst ratings
Strong Buy
Strong Buy 60%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Tyra Biosciences is a promising biotechnology company with a focused pipeline of precision medicines for targeted oncology and genetically defined conditions. Powered by their in-house precision medicine platform, SNAP, the company is able to rapidly and accurately design and predict the efficacy, selectivity, and tolerability of their drug candidates. With promising clinical data for their FGFR3, FGFR4/3, and FGFR1/2/3 drug candidates, as well as a strong safety profile, Tyra has potential for success in the competitive biotechnology market.

Bears say

Tyra Biosciences is facing several fundamental challenges, with its most recent clinical data falling well below expectations and a narrower outlook for dabogratinib after a second oncology dataset failed to demonstrate the expected efficacy. Its current pipeline is heavily reliant on the success of dabogratinib and TYRA-200, which carry significant risks and uncertainties. The company's limited market niche and potential for dilution also present concerns, further contributing to a negative outlook on its stock.

Tyra Biosciences (TYRA) has been analyzed by 10 analysts, with a consensus rating of Strong Buy. 60% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Tyra Biosciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Tyra Biosciences (TYRA) Forecast

Analysts have given Tyra Biosciences (TYRA) a Strong Buy based on their latest research and market trends.

According to 10 analysts, Tyra Biosciences (TYRA) has a Strong Buy consensus rating as of Sep 22, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $48.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $48.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Tyra Biosciences (TYRA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.